Weight loss with GLP 1 medicines does not result in a disproportionate loss of muscle mass or function in obese mice and humans: Cell Reports Medicine Cagrilintide is not associated with clinically relevant QTc prolongation: A thorough QT study in healthy participants Gabe 2024 Diabetes, Obesity and Metabolism Wiley Online Library Semaglutide ameliorates cardiac remodeling in male mice by optimizing energy substrate utilization through the Creb5 NR4a1 axis Nature Communications Curious about the latest breakthrough in weight loss and diabetes treatment? Discover the power of CagriSema, a cutting edge dual therapy combining semaglutide and kegrylentide that's showing remarkable promise for safe and Novo Nordisk's dosing in CagriSema obesity drug trial puzzles investors Reuters Efficacy and safety of co administered once weekly cagrilintide 24 mg with once weekly semaglutide 24 mg in type 2 diabetes: a multicentre, randomised, double blind, active controlled, phase 2 trial The Lancet